Lanreotide Sun

Lanreotide acetate, the active ingredient in Lanreotide Sun, is a somatostatin analog presented as an injection for subcutaneous use. It treats acromegaly and certain hormone‑secreting neuroendocrine tumors in adult patients.

GNH USA supplies Lanreotide Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanreotide Sun is used to control hormone‑driven conditions within the endocrine and neuroendocrine disease spectrum. - Acromegaly: reduces growth hormone and IGF‑1 levels, helping to control disease activity and improve symptoms. - Carcinoid tumors: inhibits secretion of vasoactive peptides, aiding in symptom control of functional neuroendocrine tumors. - Gastroenteropancreatic neuroendocrine tumors: suppresses hormone production and may limit tumor progression in hormone‑secreting gastrointestinal tumors.

Lanreotide Sun may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the subcutaneous injection site. - Gastrointestinal disturbances: nausea, abdominal pain, diarrhea, or constipation. - Hyperglycemia: elevated blood glucose levels, particularly in patients with diabetes. - Gallbladder abnormalities: formation of gallstones or biliary sludge.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe hypersensitivity reactions: anaphylaxis, angioedema, or skin rash requiring immediate medical attention. - Cardiac arrhythmias: irregular heart rhythms that may require monitoring.

Before initiating Lanreotide Sun, clinicians should consider several precautionary measures to ensure safe use. - Glucose monitoring: regularly assess blood glucose, especially in diabetic patients, as the drug can alter glycemic control. - Gallbladder assessment: evaluate for gallstones or biliary disease prior to treatment and monitor during therapy. - Pancreatitis vigilance: discontinue if signs of acute pancreatitis develop. - Renal and hepatic function: adjust therapy in patients with severe impairment after clinical evaluation. - Hypersensitivity: avoid use in individuals with known allergy to lanreotide or any excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide Sun can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Concomitant somatostatin analogs: additive hormonal suppression may increase risk of severe side effects. - Cyclosporine: may raise lanreotide plasma concentrations, requiring dose adjustment. - Insulin or oral hypoglycemic agents: enhanced glucose‑lowering effect may cause hypoglycemia; monitor closely.

Moderate Interactions (Monitor Closely): - Quinidine: may alter lanreotide metabolism, necessitating therapeutic drug monitoring. - Warfarin: potential change in anticoagulant effect; monitor INR. - Glucocorticoids: may affect blood glucose and electrolyte balance; observe patient response.